approval · primary record
AMIVANTAMAB-VMJW
FDA · BLA · 2025-11-07
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2025-11-07 |
| Approval events | 1 |
| Brand | RYBREVANT |
| Sponsor | JANSSEN BIOTECH |
| Route | INJECTION |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2025-11-07 | FDA | BLA | RYBREVANT | JANSSEN BIOTECH | INJECTION |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:29:58.910Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:amivantamab-vmjw
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab-Vmjw · compound